A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Фаза 4 – наблюдение след одобрението на пазара
Заболявания:
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic
Спонсор: Eli Lilly and Company
Налично на:
БГ
Обобщение
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Кой може да участва
Inclusion Criteria:
* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Exclusion Criteria:
* This is not applicable to this study
БГ
EN